Skip to main content
Amir  A. Jazaeri, MD, Obstetrics & Gynecology, Houston, TX

Amir A. Jazaeri MD FACS, FACOG

Gynecologic Oncology


Vice Chair for Clinical Research and Director of the Gynecologic Cancer Immunotherapy Program Department of Gynecologic Oncology & Reproductive Medicine University of Texas MD Anderson Cancer Center Vice chair for clinical research

Join to View Full Profile
  • 1515 Holcombe BlvdHouston, TX 77030

  • Phone+1 713-792-6161

Dr. Jazaeri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Texas M D Anderson Cancer Center
    University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2000 - 2004
  • University of Virginia Medical Center
    University of Virginia Medical CenterResidency, Obstetrics and Gynecology, 1996 - 2000
  • University of Virginia School of Medicine
    University of Virginia School of MedicineClass of 1996

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2024 - Present
  • AZ State Medical License
    AZ State Medical License 2024 - 2027
  • TN State Medical License
    TN State Medical License 2024 - 2027
  • WA State Medical License
    WA State Medical License 2024 - 2027
  • GA State Medical License
    GA State Medical License 2024 - 2026
  • LA State Medical License
    LA State Medical License 2024 - 2026
  • TX State Medical License
    TX State Medical License 2002 - 2026
  • Obstetrics & Gynecology
    American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • Gynecologic Oncology
    American Board of Obstetrics and Gynecology Gynecologic Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

Lectures

  • Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical c... 
    2019 ASCO Annual Meeting - 6/1/2019
  • A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or pe... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
    UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive ManagementSeptember 10th, 2024
  • IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
    IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive ManagementSeptember 9th, 2024
  • Immunotherapy Clinical Trial Allows Cervical Cancer Survivor to Thrive
    Immunotherapy Clinical Trial Allows Cervical Cancer Survivor to ThriveAugust 8th, 2024

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: